A federal jury ordered Medtronic to pay US$88,000,000 in compensatory damages over injuries linked to Covidien hernia mesh, while Medtronic Canada received Health Canada approval for its Affera Integrated Mapping and Ablation System for treating atrial fibrillation and atrial flutter. The record-setting mesh verdict sharpens attention on legal and manufacturing risks, but the near-term investment focus still centers on execution in Cardiac Ablation Solutions and other growth platforms. The new Health Canada licence deepens Medtronic's footprint in atrial fibrillation treatment by adding a second pulsed field ablation option alongside PulseSelect, which could influence catheter utilization and procedure volumes if adoption continues. Medtronic's narrative projects $41.5 billion revenue and $6.6 billion earnings by 2029, requiring 4.5% yearly revenue growth and about a $1.8 billion earnings increase from $4.8 billion today. Some of the lowest ranked analysts were already assuming slower growth, with revenue around US$38.6 billion and earnings of about US$6.2 billion by 2029, and this latest mesh verdict could reinforce that more cautious view if concerns about legal and execution risks in CAS and other platforms start to broaden.
Medtronic PLCRecord $88M mesh verdict is negative, but Health Canada approval for Affera is positive, creating mixed impact.
